This is a proposal describing a study to test the hypothesis that: The macrolide, erythromycin, normally used to treat individuals with community-acquired pneumonia, causes significant antibiotic resistance in patients in Europe but not individuals in the United States. 9 sources
To assess the prevalence of macrolide resistance (Erythromycin) among pneumococci in Europe and the United States and difference in frequency of Erythromycin use in both countries for respiratory infections. To identify the prevalent serotypes that cause pneumonia in both regions.
This will basically be a retrospective analysis of data collected by Public Health laboratories in Europe and institutions such as the Center for Disease Control in the United States. The two continents should be divided into 4 geographical regions each for the sake of clarity and convenience. Previous data relating to pneumococci isolated from patients with suspected pneumonia during a chosen specific period of time spanning about 5...
[ View Full Essay]